CG
FATE icon

Cutler Group’s Fate Therapeutics FATE Stock Holding History

Cutler Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200
Closed -$3K – 5563
2021
Q3 		$3K Buy
+200
New +$15.7K ﹤0.01% 4793
2020
Q2 		– Sell
-5,500
Closed -$1K – 4518
2020
Q1 		$1K Hold
5,500
– – ﹤0.01% 3690
2019
Q4 		$1K Buy
+5,500
New +$87.3K ﹤0.01% 3654

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Cutler Group's FATE Position: Q1 2022 in Review

Cutler Group sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 209 shares — an estimated $12K sold.

Cutler Group first reported a position in FATE in Q2 2018 and held it in 8 quarters. The position peaked at $130K in Q3 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Cutler Group reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 209 Fate Therapeutics shares in Q1 2022, an estimated $12K.
  • Cutler Group first reported a position in Fate Therapeutics in Q2 2018 and held it in 8 quarters.
  • Cutler Group's Fate Therapeutics position peaked at $130K in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.